相关实验视频

Updated: Apr 28, 2026

Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging

Tracking the Mammary Architectural Features and Detecting Breast Cancer with Magnetic Resonance Diffusion Tensor Imaging

Published on: December 15, 2014

MTDH基因多态和侵入性导管性乳腺癌之间的新兴关联:一个病例对照研究

Yan Huang¹, Dan Dai², Li Zhu²

¹Department of Pathology, The First People's Hospital of Linping District, #369 Nanyuan Street Yingbin Road, Linping District, Hangzhou, Zhejiang, China. hy9902004@126.com.

Discover oncology

|July 8, 2024

概括

MTDH基因单核酸多态 (SNPs) 与侵袭性导管性乳腺癌 (IDC) 风险增加有关. 这些MTDH基因变异可能有助于IDC亚型和选择适当的疗法.

科学领域:

遗传学和基因组学遗传学和基因组学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

特定基因多态化在癌症发展中的作用是一个活跃的研究领域.
识别侵入性导管性乳腺癌 (IDC) 的遗传风险因素对于早期检测和预防至关重要.

研究的目的:

调查MTDH基因中单核酸多态 (SNPs) 与患入侵导管乳腺癌 (IDC) 的风险之间的关联.

主要方法:

一项涉及300名IDC病例和565名来自中国东部的无癌症对照的病例控制研究.
使用TaqMan实时PCR对三种MTDH基因SNP (rs1311,rs16896059,rs2449512) 的基因定型.
使用后勤回归分析,分析MTDH SNPs与IDC风险之间的关联.

主要成果:

三个MTDHSNP (rs1311,rs16896059,rs2449512) 显示出与IDC风险增加的显著关联.
特定的MTDHSNP基因型和单元型与各种患者亚组的更高敏感性有关,这表明在IDC亚型化中的潜在作用.
该研究确定了MTDH多态和临床病理特征之间的相关性,包括瘤大小,更年期状态,临床阶段和激素受体状态.

结论:

MTDH基因多态性与侵袭性导管性乳腺癌 (IDC) 的高风险显著相关.
MTDH基因变异可能作为分类IDC亚型的潜在生物标志物.
这些发现表明MTDH多态可能有助于乳腺癌患者的治疗选择.

关键词:

在这段时间里,MTDH MTDH 乳腺癌是什么? 乳腺癌是什么侵袭性的侵袭性的多态性多态性多态性易感性易感性易感性

更多相关视频

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

相关概念视频

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...